even express caveolins or have caveolae-type organelles. Among these cells, macrophages, endothelial and smooth muscle cells all play key roles in the development of atherosclerosis [6] . Cav-1 is considered a negative regulator of endothelial nitric oxide synthase and plays an important role in influencing various aspects of cardiovascular functions [7] . Previous study has shown that atherosclerotic lesion area is markedly reduced in apoE -/-Cav-1 -/-double knockout mice, which indicates that a lack of Cav-1 inhibits atherogenesis [7] . However, neointima formation is exacerbated in the carotid arteries of Cav-1 -/-mice after surgical ligation [8] . Thus, endothelial cell Cav-1 may have a pro-atherogenic role and smooth muscle cell Cav-1 the opposite role. So Cav-1 may positively or negatively influence the development of vascular disease, depending on the cell type and the metabolic pathways regulated by this protein [8] . But the role of macrophage Cav-1 on atherosclerosis remains unclear.
Previous studies have suggested that Cav-1 expression is regulated by peroxisome proliferator-activated receptor ␥ (PPAR ␥ ) in cell types such as human adenocarcinoma and hepatic cells [9, 10] . PPAR ␥ is an important transcription factor and is involved in atherosclerosis progression [11] . Recently, we have demonstrated that PPAR ␥ 1 gene transfer exerts beneficial effects in attenuating atherosclerosis progression and stabilizes vulnerable plaques [12] . To determine the relationship between Cav-1 and PPAR ␥ 1 in vascular cell and further identify a role of Cav-1 on atherosclerosis, we chose to use small interfering RNA (siRNA) to transiently and specifically knockdown expression of Cav-1 and adenovirus-mediated PPAR ␥ 1 gene overexpression in RAW264.7 cells. We investigated whether PPAR ␥ 1-induced Cav-1 could attenuate established atherosclerotic lesions in apoE -/-mice.
Materials and Methods
Synthesis and Transfection of siRNA siRNA sequences targeting mice Cav-1 gene (AACGCGCA-CACCAAGGAGATT) were synthesized (Dharmacon Inc., Lafa yette, Colo., USA). The sequence (AACCAGAAGGGACACA-CAGTT) targeting the human Cav-1 gene with no apparent effects in mice cells was used as a negative control (Ctr-siRNA). For transfection, cells were plated on 6-well plates. Transfections were performed with TransIT-TKO reagent (Mirus Corp., Madison, Wisc., USA), as directed by the manufacturer. Each well received 10 n M siRNA in a volume of 1 ml, in triplicate.
Recombinant Adenovirus
We constructed recombinant adenovirus containing the mouse PPAR ␥ 1 cDNA (Ad/mPPAR ␥ 1) as described by He et al. [13] . The plasmid of PCMX-mPPAR ␥ 1 and the AdEasy vector were provided by Dr. Ronald M. Evans (Salk Institute, San Diego, Calif., USA) and Dr. Tong-Chun He (Howard Hughes Medical Institute, Chevy Chase, Md., USA), respectively.
Cells and Cell Culture
A murine macrophage cell line, RAW264.7, from the American Type Culture Collection (Manassas, Va., USA) was used for all experiments. Cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, Calif., USA) supplemented with 5 m M L -glutamine, 100 units/ml penicillin and streptomycin, and 10% fetal calf serum, at 37 ° C and 5% CO 2 . For experiments, cells were cultured in the same media, except 0.2% fetal calf serum was used. Adenovirus was dissolved in phosphate-buffered saline (PBS). RAW264.7 cells were randomly divided into 5 groups: AdPPAR ␥ 1 group and AdGFP group (both multiplicity of infection = 5), Cav-1-siRNA group, PPAR ␥ 1-treated Cav-1-siRNA group and Ctr-siRNA group. Fresh medium was added 5 h after transfection, and experiments were conducted 48 h after transfection.
Immunocytochemistry
Cells treated with AdGFP or AdPPAR ␥ 1 were harvested and fixed in ice acetone for 15 min and stored at -20 ° C until use. Fixed cells were incubated with 5% bovine serum albumin (BSA; SigmaAldrich, St. Louis, Mo., USA) for 20 min, then treated with a mouse monoclonal anti-mouse PPAR ␥ antibody (1: 50) or rabbit polyclonal anti-human Cav-1 antibody (1: 100; Santa Cruz Biotechnology, Santa Cruz, Calif., USA) overnight at 4 ° C and incubated with the secondary biotinylated anti-mouse and anti-rabbit antibody for 30 min after a washing in PBS (3 ! 5 min). After a further washing in PBS, streptavidin conjugate was applied for 30 min. Then cells were washed again with PBS and counter-stained by 3,3 -diaminobenzidine for 5-10 min. In negative controls, the same method was used except for omitting incubation with the primary antibody.
Reverse-Transcriptase PCR
Total RNA from RAW264.7 cells of different intervention groups and control group was isolated by the Rneasy method (Trizol reagent) according to the manufacturer's protocol. Then, the amount and quality of RNA were determined before analysis. Contaminating DNA was degraded by use of 1 unit DNase-I (Invitrogen, Karlsruhe, Germany) per microgram of total RNA. mRNA levels of PPAR ␥ 1 and Cav-1 were determined by RT-PCR. Briefly, 1 g of total RNA was used to generate first-strand cDNA with use of an oligo dT oligodeoxynucleotide primer (T [12] [13] [14] [15] [16] [17] [18] ) following the description of M-MLV Reverse Transcriptase (Promega, Madison, Wisc., USA). The primers were made by Invitrogen Life Technologies. ␤ -actin (NM007393): 5 -ATGGATGAC-GATATCGCT-3 , 5 -ATGAGGTAGTCTGTCAGGT-3 (569 bp). PPAR ␥ 1 (U01841): forward 5 -GTCGACATGGTTGACACAGA-GATGC-3 , reverse 5 -TCTAGACTAATACAAGTCCTTGTA-3 (1,440 bp). Caveolin-1 (NM007616): forward 5 -CAGCATG-TCTGGGGGTAAAT-3 , reverse 5 -TGCTTCTCATTCACCTC-GTCT-3 (341 bp). Equal amounts of cDNA were used in triplicate and amplified with use of the Premix Ex Taq TM kit (Takara Bio Inc., Otsu, Japan) according to the manufacturer's instructions. Reactions were prepared with 1.5 units of Taq DNA polymerase, 10 m M Tris/HCl, pH 9.0 at room temperature, 50 m M KCl, 1.5 m M MgCl 2 , 0.2 m M dNTPs, 0.4 M sense and antisense primers, and 71 overlaid with 40 l of mineral oil. Amplification was undertaken by denaturation at 95 ° C for 30 s, annealing at 57 ° C for 30 s and extension at 72 ° C for 1.5 min with a final 7 min extension time at 72 ° C. RT-PCR products were analysed in a 2% agarose gel containing ethidium bromide. The quantification value of the bands in the gel was designated the 'optical density' (pixels). Amplification efficiencies were validated and normalized against ␤ -actin.
Immunoblotting Experiments
For Western blot analysis, about 10 7 cells were washed in PBS and solubilized buffer (50 mmol/l Tris-HCl, pH 7.4, 125 mmol/l NaCl, 0.1% NP-40, 5 mmol/l NaF, 1 mmol/l PMSF, 1 ng/ml leupeptin, 10 ng/ml soybean trypsin inhibitor, 1 ng/ml aprotinin, 10 ng/ml N-tosyl-L -phenylalanyl chloromethyl ketone) for 60 min on ice. Lysates were centrifuged at 2,500 g for 5 min. The protein concentrations in RAW264.7 cells were measured by the bicinchoninic acid protein assay, with BSA used as the protein standard. 20 g of protein extracts were mixed with SDS-PAGE sample buffer, boiled for 5 min, electrophoresed on 10% SDS-polyacrylamide gel, then transferred to PVDF membranes (Millipore, Billerica, Mass., USA). After subsequent washing in 25 m M Trisbuffered saline with 0.05% Tween-20 (TTBS), the unspecific binding sites were saturated by incubation with 10% non-fat dry milk in TTBS for 1 h at room temperature. The membranes were incubated overnight at 4 ° C with primary antibody against PPAR ␥ or Cav-1 (both 1: 2,000). The secondary anti-mouse and anti-rabbit antibodies (1: 100) were diluted in 2.5% non-fat dry milk in TTBS and incubated for 1 h at room temperature; chemiluminescent signal was developed by use of ECL Advance (GE Healthcare, Amersham, UK). Anti-actin monoclonal antibody (1 g/ml dilution; Sigma-Aldrich) was hybridized to membranes to serve as a measure of loading control. Controls involved omitting the primary antibody. Densitometric analysis involved use of NIH Image 1.62 software. Ratios for PPAR ␥ / ␤ -actin and Cav-1/ ␤ -actin protein were calculated for each sample and expressed as the mean 8 SEM. The experiment was performed in triplicate and repeated 3 times.
Cholesterol Efflux Assay
Based on slight modification of Ghering AB's assay for cholesterol efflux [14] , RAW264.7 cells on 24-well plates were infected with control, or Cav-1 siRNAs or AdPPAR ␥ 1 as described above. At 48 h after transfection, the cells were labeled for 24 h with 0.5 Ci/ml 1,2-[3H] cholesterol (GE Healthcare). RAW264.7 cells from different intervention groups and control group were then washed 3 times with PBS and incubated for 2 h at 37 ° C with RPMI 1640, 0.2% fatty acid free BSA. The medium was replaced with fresh RPMI 1640/BSA with or without pure lipid-free human apoA-I (10 g/ml) and incubated at 37 ° C for 6 h. The media were then collected and analyzed by liquid scintillation counting. Cells were dissolved in 0.2 N NaOH and the cellular radioactivity was determined. The efflux is expressed as a percent of the total [3H] cholesterol radioactivity present in the cells + the efflux medium.
Animal Protocol
Male apoE-deficient mice on a C57Bl/6 background (20 weeks of age) fed a regular chow were purchased from the department of medical science at Beijing University, then bred and maintained in the center for animal experiments at Shandong University. The mice were kept in separate cages in a 12-hour light/dark cycle, allowed to acclimatize for 1 week before the study started, then fed a Western-type diet containing 21% fat (wt/vol), and 0.15% cholesterol (wt/wt) until sacrifice. New batches of food were prepared weekly and stored at 4 ° C. All animals had free access to water. AdPPAR ␥ 1 (5 ! 10 8 pfu) or AdGFP (5 ! 10 8 pfu; vehicle control) diluted to a total volume of 200 l was injected into the tail vein of each group of mice (at 40 weeks of age, n = 20). We sacrificed all animals 4 weeks later. The investigation conformed with the institutional animal care and use committee protocol at Shandong University and were consistent with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Lipoprotein Profiles
Blood samples (approx. 0.4 ml/mouse) were taken from the vena jugular of each mouse before the treatments and before sacrifice for assays of lipids and lipoproteins. Blood samples were obtained from each animal in a fasting state and drawn into EDTA-coated microcapillary tubes. Plasma was isolated from whole blood and glucose levels were determined. Serum levels of total cholesterol, triglyceride, low-density lipoprotein and highdensity lipoprotein were measured by enzymatic assays using an automated bichromatic analyzer (Hitachi 7170A, Tokyo, Japan).
Tissue Preparation
After mice were anesthetized by intraperitoneal injection of pentobarbital (30 mg/kg), the chest was opened and the heart was exposed. The heart was perfused with cold PBS for 3 min via a catheter in the left ventricle from its apex and a free efflux of blood from the heart was allowed by cutting the right atrium, followed by perfusion fixation with phosphate-buffered 4% paraformaldehyde, pH 7.0-7.4, for 7 min. The perfusion pressure was kept constant at 100 mm Hg. The heart containing the aortic sinus and aortic arch was rapidly harvested and fixed overnight at room temperature in phosphate-buffered 4% paraformaldehyde, pH 7.0-7.4. The adventitial side of the thoracic aorta was carefully dissected free from fat. The stubs of the intercostal arteries were trimmed close to the aorta. Under a dissection microscope, the remaining aortic arch and descending aorta were fixed in 4% paraformaldehyde for measurement of the surface area covered by lipid-staining lesions. The frozen cross-sections of the aortic sinus embedded in Optimal Cutting Temperature compound (Sakura Finetek, Torrance, Calif., USA) were mounted on slides for histology and immunohistochemistry. The liver, the remaining aortic arch and the descending aorta were separated and quickly fixed or frozen. mRNA levels of PPAR ␥ 1, Cav-1, liver X receptor ␣ (LXR ␣ ) and ATP-binding cassette transporter A1 (ABCA1) from the liver of apoE -/-mice were determined by quantitative real-time RT-PCR. The primers were also made by Invitrogen Life Technologies. ␤ -actin: 5 -CACTGTGCCC-ATCTACGA-3 , 5 -GTAGTCTGTCAGGTCCCG-3 . PPAR ␥ 1: forward 5 -GCCCAGGCTTGCTGAACG-3 , reverse 5 -GGAG-CACCTTGGCGAACA-3 . Caveolin-1: forward 5 -CAGCATG-TCTGGGGGTAAAT-3 , reverse 5 -TGCTTCTCATTCACCTC-GTCT-3 . ABCA1: forward 5 -CCAGTAACTACAGTGGCGG-CAA-3 , reverse 5 -TCTTCTATGTGGAGTCGCTTTT-3 . LXR ␣ : forward 5 -TGAAGCGGCAAGAAGAGGAACA-3 , reverse 5 -GATGGCAATGAGCAGAGCAAAC-3 . Equal amounts of cDNA were used in triplicate and amplified with use of the SYBR Premix Ex Taq kit (Takara Bio Inc.) according to the manufacturer's instructions. Reactions were prepared with 10 l SYBR Premix Ex Taq, 0.8 l forward primer (5 M ), 0.8 l reverse primer (5 M ), and 2 l cDNA, in a final volume of 20 l. The reactions were carried out on the LightCycler 4.0 (Roche, USA) for 10s at 95 ° C, followed by 40 cycles with denaturation at 95 ° C for 15 s, annealing at 52-55 ° C for 5 s, and extension at 72 ° C for 10 s. Amplification efficiencies were validated and normalized against ␤ -actin, and the products were calculated by the standard curve method for quantitation according to LightCycler 4.0. The qRT-PCR products were analyzed by electrophoresis on a 2% Tris-acetate-EDTA agarose gel. Immunoblotting was used to determine the levels of Cav-1 protein, similar to cellular protein level assay.
Histology and Immunohistochemistry
Transverse 7-m cross-sections of the aortic root were prepared, serially mounted, and routinely stained with Oil Red O, hematoxylin and eosin, and Movat's pentachrome staining for differentiation of muscle, various connective tissue components, mucinous secretions and intra-cytoplasmic structures. The remaining sections were used for immunohistochemical analysis. Frozen serial sections were treated with 0.3% H 2 O 2 in PBS to block endogenous peroxidase activity, followed by blocking in 5% BSA. Sections were incubated with either a mouse monoclonal antibody against mouse PPAR ␥ at 1: 50 dilution (Santa Cruz Biotechnology), purified rabbit polyclonal antibody against human Cav-1 at 1: 50 dilution (Santa Cruz Biotechnology) or a purified rat monoclonal antibody against mouse macrophages (MOMA-2; Millipore) at 1: 25 dilution. For ␣ -smooth muscle actin studies, a kit (Sigma-Aldrich) was used. Peroxidase-labeled anti-mouse, anti-rabbit or anti-rat antibodies, at 1: 50 dilution, were used as second antibodies. The activity of peroxidase was revealed with diaminobenzidine (Merck), yielding a yellow-brown deposit. The sections were then counterstained with hematoxylin. Negative controls included sections with the first antibodies omitted.
Data and Statistical Analysis
All experiments in vitro were performed at least 3 times. All data are means 8 SEM, unless otherwise specified. Differences between groups were determined by 2-way ANOVA and a multiple comparison test. A p ! 0.05 was considered significant. All images were captured by use of an Olympus microscope equipped with a video camera and analyzed by NIH Image 1.62 software.
Results

PPAR ␥ 1 Gene Transfer Induces Caveolin-1 Expression in Macrophages
The protein Cav-1 is the major coat protein for the organelle caveolae. To determine whether PPAR ␥ 1 gene transfer induced the expression of Cav-1 in macrophages, RAW264.7 cells were incubated with AdPPAR ␥ 1. Compared with vector control cells (AdGFP), these cells constitutively overexpressed PPAR ␥ 1, and immunocytochemistry showed Cav-1 localized in the membrane compartment ( fig. 1 a) . Compared with the AdGFP group, AdPPAR ␥ 1-treated cells showed significantly increased Cav-1 expression in the cellular membrane ( fig. 1 a, b) . qRT-PCR also demonstrated that AdPPAR ␥ 1-treated cells showed significantly increased Cav-1 mRNA levels ( fig. 1 c) . Thus, PPAR ␥ 1 overexpression induced increased Cav-1 mRNA and protein levels in RAW macrophages. fig. 1, 2; www.karger.com/doi/10.1159/000235927). We also found Cav-1 levels were markedly increased in atheromatous plaques of AdPPAR ␥ 1-infected mice as compared with AdGFP-infected mice, as assessed by immunohistochemistry (89 8 2% vs. 47 8 1%, p ! 0.05; fig. 2 fig. 4 a, b) . Typical atheromas with well-developed, lipid-rich cores and foam cell infiltration but not fibrous tissue proliferation were observed in some sections from the AdGFP-infected group ( fig. 4 a, b) . The cross-sectional lesion areas of AdPPAR ␥ 1-infected mice were significantly smaller than those of the AdGFP-infected mice (0.511 8 0.351 vs. 1.328 8 0.737 mm 2 , p ! 0.05; fig. 4 c) . En face staining surface atherosclerotic lesions of AdPPAR ␥ 1-infected mice were smaller in number than those of the AdGFP-infected group (24 vs. 38%, p ! 0.05; fig. 4 d) . Compared with the AdGFP-infected mice, AdPPAR ␥ 1-infected mice showed significantly downregulated lipid deposition in plaques ( fig. 4 b) , and the macrophage area in plaque was greatly decreased ( fig. 4 e, g ), whereas the smooth muscle cell area was significantly increased ( fig. 4 f, g ). Similarly, PPAR ␥ 1 transfection also effectively preserved collagen and proteoglycan deposition in plaque ( fig. 4 h) . Thus, PPAR ␥ 1-induced Cav-1 upregulation attenuates the progression of established atherosclerotic lesions in apoE-deficient mice.
PPAR ␥ 1 Gene Transfer Induces
Caveolin-1 Expression in Macrophages, Endothelial and Smooth Muscle Cells, which Make up Atheromatous Plaques Many tissues, such as the liver and the aorta, normally express PPAR ␥ and Cav-1 at a lower level. 28 days after adenovirus injection, PPAR ␥ immunoreactivity in the liver and the aorta was markedly upregulated in AdPPAR ␥ 1-infected mice but not AdGFP-infected mice (online suppl.
PPAR ␥ 1-Induced Caveolin-1 Attenuates Lipoprotein Metabolic Disorders
To investigate possible mechanisms of the anti-atherogenic effects of PPAR ␥ 1-induced Cav-1 upregulation in apoE-deficient mice, lipoprotein levels were evaluated. Table 1 shows the plasma concentrations of lipid and lipoprotein profiles. High-density lipoprotein cholesterol level was increased, by 28.4%, in AdPPAR ␥ 1-infected mice compared with AdGFP-infected mice, and there was no significant difference in plasma low-density lipoprotein, total cholesterol or triglyceride levels between the 2 groups. The mechanism of the beneficial effects of PPAR ␥ 1-induce Cav-1 upregulation on lipid profiles remains to be determined.
Cav-1 Induced by PPAR ␥ 1 Enhanced Cholesterol
Efflux to apoA-I Our demonstration of PPAR ␥ 1-induced Cav-1 upregulation raised the question of its enhancement of cholesterol efflux from foam cells. In the murine macrophage cell line RAW264.7, PPAR ␥ 1-induced Cav-1 upregulation enhanced cholesterol efflux ( fig. 5 ). Cholesterol acceptors used were lipid-poor apoA-I. PPAR ␥ 1 is thought to promote cholesterol efflux through LXR-dependent and independent pathways [15] . To further test whether caveolin-1 is very important for cholesterol efflux, we utilized small interfering RNA for Cav-1. The results showed an efficient and specific knockdown of caveolin-1 expression (80%), which resulted in the remarkable reduction of cholesterol efflux. In addition, PPAR ␥ 1-treated Cav-1-siRNA RAW264.7 cells showed a greater ability to stimulate cholesterol efflux than Cav-1-siRNA RAW264.7 cells, but far less than Ctr-siRNA RAW264.7 cells and PPAR ␥ 1-treated RAW264.7 cells (p ! 0.05; fig. 5 ).
PPAR ␥ 1 Gene Transfer Upregulates Cholesterol Efflux-Related Gene Expression in Liver of apoE-Deficient Mice
Cholesterol efflux enhancement may contribute to the beneficial effects of PPAR ␥ 1-induced Cav-1 upregulation on lipid profiles. In this study, we have demonstrated Cav-1 induced by PPAR ␥ 1 enhanced cholesterol efflux to apoA-I. Except for Cav-1 and PPAR ␥ 1, cholesterol efflux pathways involve a variety of factors, including the nuclear orphan receptors LXRs, as well as the proteins ABCA1 and SR-BI [16] . Previous study showed that PPAR ␥ was not required for efflux from cholesterol-loaded macrophages via HDL or apoA-mediated pathways. To further assess the mechanism of enhanced cholesterol efflux from foam cells under PPAR ␥ 1 gene transfer, we quantified the corresponding mRNA levels of the cholesterol efflux-related molecules. A marked overexpression of ABCA1 and LXR ␣ was discerned in AdPPAR ␥ 1-infected mice but not in AdGFP-infected mice (ABCA1: 0.35 8 0.07 vs. 0.12 8 0.05, p ! 0.05; LXR ␣ : 0.29 8 0.03 vs. 0.09 8 0.02, p ! 0.05; fig. 3 ).
Discussion
Caveolae are 50-to 100-nm invaginations of the cell surface plasma membrane and are present in terminally differentiated cells. They are characterized by the presence of Cav-1, sphingolipids and cholesterol. Physiologically, the loss of caveolae results in impaired cholesterol homeostasis, insulin sensitivity, nitric oxide activity, calcium signaling and cardiac function. Although caveolinknockout mice are useful to delineate the importance of caveolae in a given response, other questions are difficult to assess because the loss of Cav-1 and Cav-3 abolishes both the caveolae organelle as well as the pathways regulated by protein-protein or protein-lipid interactions with the caveolins [17] .
Cav-1, the major structural protein of caveolae, is present in several cell types known to play a role in the development of atherosclerosis [18] . Cav-1 is thought to play an important role in the regulation of cellular cholesterol homeostasis, a process that requires proper control to limit and prevent cholesterol accumulation and, eventually, atherosclerosis. Several lines of evidence now suggest that Cav-1 might play a proatherogenic role [19, 20] . Loss of Cav-1 provides the molecular genetic evidence to support caveolar transcytosis of modified lipoproteins (from the blood to the sub-endothelial space) as a critical initiating step in atherosclerosis [21] . Frank et al. identified caveolae-type organelles as critical for atherosclerotic lesion progression in mice [1] . In endothelial cells, Cav-1 is upregulated on LDL exposure. Moreover, downregulation of Cav-1 is associated with reduced uptake of oxidized LDL by endothelial cells, because caveolae are proposed to play a major role in the transcytosis of native and modified LDL, with smooth muscle cell Cav-1 having the opposite role [1, 4, 5, 7, 21] . Monocyte-derived macrophages also play an important role in the development of atherosclerosis. They take up large amounts of modified lipids present in the subendothelial space of the arterial wall and form fatty streak lesions [22] . Evidence for caveolin expression in macrophages, however, has been scarce and conflicting. Macrophages were found not to express caveolin [23] . As well, immunoblot analyses have indicated Cav-1 expression in THP-1 cells but not J774 or RAW macrophages [24] . Contrary to these reports, Cav-1 mRNA was recently detected in J774 and RAW macrophages on RT-PCR [25] . Cav-1 may positively or negatively influence the development of vascular disease, depending on the cell type and the metabolic pathways regulated by this protein. Therefore, whether vascular cells, especially those making up atherosclerotic plaque, even express caveolins or have caveolae-type organelles and whether caveolin-1 is pro-atherogenic or anti-atherogenic are currently debated.
In the current study, immunohistochemical analysis revealed Cav-1 expressed in the cellular membrane of RAW macrophages. Immunoblotting and RT-PCR results confirmed this phenomenon. We also found PPAR ␥ expressed in RAW macrophages and in macrophage-derived foam cells of atherosclerotic lesions of apoE-deficient mice. Here, we provide direct evidence that PPAR ␥ 1 transfection attenuates the progression of established atheroma by reducing deposition of lipids and macrophages and increasing content of smooth muscle cells. Previous studies have suggested that Cav-1 expression is regulated by PPAR ␥ in other cell types, such as human adenocarcinoma and hepatic cells [9, 10] . Whether Cav-1 expression is regulated by PPAR ␥ 1 in RAW macrophages, even in aorta of apoE-deficient mice remains unclear. Our results clearly established that overexpression of PPAR ␥ 1 triggered the upregulation of Cav-1 genes in RAW macrophages. Our in vivo experimental data strongly suggested that this overexpression led to the upregulation of the Cav-1 gene in the aorta and the liver of apoE-deficient mice. Indeed, upregulated Cav-1 was chiefly distributed and expressed in endothelial cells, smooth muscle cells and macrophages, which make up the vessel wall and atheromatous plaques. Recently, Llaverias et al. [26] found that rosiglitazone, a PPAR ␥ agonist, upregulated Cav-1 in THP-1 cells through a PPAR-dependent mechanism. Moreover, the upregulation of Cav-1 in the liver 6 days after injection of AdPPAR ␥ 1 into PPAR ␣ -/-mice was verified by Affymatrix microarray chips [10] .
At present, the mechanism regulating Cav-1 expression remains unclear. The functionality of the potential binding site was verified by a previous study with a double-stranded oligonucleotide containing the PPAR response element identified in the human Cav-1 promoter used as a probe [26] . Accordingly, we propose that the effect of PPAR ␥ 1 on Cav-1 expression may be mediated by transcription activation upon binding of PPAR ␥ /RXR heterodimers to the newly identified PPAR response element in the promoter of the murine Cav-1 gene, which may explain the phenomenon in part. However, further studies are needed to ascertain the precise mechanisms.
The data suggest that Cav-1 and ABCA1 are important proteins involved in cellular cholesterol efflux. Cholesterol efflux is a pathway for removing excessive cholesterol from cells to extracellular acceptors. It is the first step of reverse cholesterol transport and plays a key role in maintaining cell cholesterol homeostasis. Impaired cholesterol efflux leads to accumulation of intracellular cholesterol and development of atherosclerosis in animal models and in humans [27, 28] . Regarding the increase, we found in high-density lipoprotein cholesterol, cholesterol efflux may be enhanced by AdPPAR ␥ 1 transfection. In this study, PPAR ␥ 1 overexpression enhanced cholesterol efflux in RAW264.7 cells and increased the mRNA level of cholesterol efflux-related molecules such as Cav-1, LXR ␣ and ABCA1 in liver extracts from apoE-deficient mice. Previous study demonstrated that Cav-1 colocalizes with ABCA1 in the caveolae and in the cytoplasmic vesicles and with cellular cholesterol [29] . Indeed, these results imply another pathway influencing cholesterol efflux, possibly a PPAR ␥ -LXR ␣ -Cav-1 regulatory pathway, similar to that observed for other genes related to cholesterol efflux, such as ABCA1 and apoE. In this current study, we acutely down-regulated the expression of caveolin-1 in RAW264.7 cells to evaluate the direct role of this protein on cholesterol efflux. Here we provide evidence that the specific down-regulation of caveolin-1 impairs cholesterol efflux to apolipoprotein A-I. Moreover, we have demonstrated, for the first time, cholesterol efflux was enhanced in PPAR ␥ treated Cav-1-siRNA RAW264.7 cells, compared with Cav-1-siRNA RAW264.7 cells. In apoE-deficient mice, only 2 regulatory pathways seem to influence cholesterol efflux: PPAR ␥ -LXR ␣ -Cav-1 and PPAR ␥ -LXR ␣ -ABCA1. This should be reevaluated using caveolin-specific silencing systems in apoE -/-mice or caveolin-1 -/-/apoE -/-mice. Therefore, further studies are needed to ascertain the precise mechanisms.
In conclusion, these data strongly support PPAR ␥ 1 gene transfer as increasing the expression of Cav-1 in RAW macrophages, especially in established atherosclerotic lesions of apoE-deficient mice. Moreover, PPAR ␥ 1-induced Cav-1 upregulation actually confers protection against atherosclerosis. This observation may be due to some potential mechanisms: (1) the effects seem to be mediated by the binding of activated PPAR ␥ 1 to a new PPAR response element in an unidentified murine Cav-1 promoter; (2) enhancement of cholesterol efflux may be mediated by PPAR ␥ -LXR ␣ -Cav-1 or PPAR ␥ -LXR ␣ -ABCA1 regulatory pathways in apoE-deficient mice; (3) with regard to enhancement of cholesterol efflux and altered lipoprotein status, PPAR ␥ 1-induced Cav-1 upregulation is likely anti-atherogenic in this model. However, we have no explanation of the net outcome on lipoprotein metabolism and lesion development of Cav-1 in apoE-deficient mice treated with PPAR ␥ 1, given the cellular data that: (1) caveolin-1 is a cholesterol-binding protein that can transport cholesterol from the endoplasmic reticulum to the plasma membrane, and (2) a major receptor for HDL, scavenger receptor SR-B1, and a scavenger receptor for modified forms of LDL, CD36, can reside in and signal in caveolae-type microdomains [30] . Regardless of the above molecular mechanisms, other mechanisms may also participate in the increased Cav-1 expression and reduced atherosclerotic lesions after PPAR ␥ 1 treatment.
